Disc Medicine (IRON) Invested Capital (2020 - 2026)

Disc Medicine (IRON) has 7 years of Invested Capital data on file, last reported at $717.8 million in Q1 2026.

• Quarterly Invested Capital rose 4.2% year-over-year to $717.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $717.8 million (up 4.2% YoY) and the FY2025 annual result came in at $769.0 million, up 62.95% from the prior year.
• Invested Capital eased to $717.8 million in Q1 2026 per IRON's latest filing, from $769.0 million in the prior quarter.
• Across five years, Invested Capital topped out at $769.0 million in Q4 2025 and bottomed at -$98.5 million in Q3 2022.
• The 5-year median for Invested Capital is $371.2 million (2023), against an average of $377.9 million.
• The widest annual swing landed in 2022, when Invested Capital plunged 167.55%; it then jumped 564.79% in 2023.
• Tracing IRON's Invested Capital over 5 years: stood at $176.6 million in 2022, then surged by 95.43% to $345.1 million in 2023, then soared by 36.74% to $471.9 million in 2024, then jumped by 62.95% to $769.0 million in 2025, then retreated by 6.66% to $717.8 million in 2026.
• Per Business Quant, the three latest IRON Invested Capital figures stand at $717.8 million (Q1 2026), $769.0 million (Q4 2025), and $602.3 million (Q3 2025).

Peer Comparison